APPENDIX A

This claim set replaces all previous claims in this application.

1. (Original) A pharmaceutical composition which comprises a pharmaceutically acceptable carrier or diluent and:

(a) an inhibitor of the RSV fusion protein; and

(b) a benzodiazepine derivative capable of inhibiting RSV replication.

2. (Original) A composition according to claim 1, wherein component (b) is a compound of formula (V), or a pharmaceutically acceptable salt thereof,



(V)

wherein:

R^1 represents C_{1-6} alkyl, aryl or heteroaryl;

R^2 represents hydrogen or C_{1-6} alkyl;

each R^3 is the same or different and represents halogen, hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkylthio, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, amino, mono(C_{1-6} alkyl)amino, di(C_{1-6} alkyl)amino, nitro, cyano, -CO_2R', -CONR'R", -NH-CO-R', -S(O)R', -$S(O)_2$R', -NH-$S(O)_2$R', -S(O)NR'R" or -$S(O)_2$NR'R", wherein each R' and R" is the same or different and represents hydrogen or C_{1-6} alkyl;

n is from 0 to 3;

R^4 represents hydrogen or C_{1-6} alkyl;

X represents -CO-, -CO-NR'-, -S(O)- or -$S(O)_2$-, wherein R' is hydrogen or a C_{1-6} alkyl group; and

R^5 represents an aryl, heteroaryl or heterocyclyl group which is substituted by a C_{1-6} hydroxyalkyl group or a -(C_{1-4} alkyl)-X_1-(C_{1-4} alkyl)-X_2-(C_{1-4} alkyl) group, wherein X_1 represents -O-, -S- or –NR'-, wherein R' represents H or a C_{1-4} alkyl group and X_2 represents -CO-, -SO- or -SO_2-, or R^5 represents –A_1-Y-A_2, wherein:

A_1 is an aryl, heteroaryl, carbocyclyl or heterocyclyl group;

Y represents a direct bond or a C_{1-6} alkylene, $-SO_2-$, -CO-, -O-, -S- or -NR'- moiety, wherein R' is a C_{1-6} alkyl group; and A_2 is an aryl, heteroaryl, carbocyclyl or heterocyclyl group.

3. (Previously presented) A composition according to claim 2 wherein R^1 is C_{1-2} alkyl or phenyl.

4. (Previously presented) A composition according to claim 2, wherein R^2 is hydrogen.

5. (Withdrawn) A composition according to claim 2 wherein R^3 is halogen, hydroxy, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} alkylthio, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, amino, mono(C_{1-4} alkyl)amino or di(C_{1-4} alkyl)amino.

6. (Withdrawn) A composition according to claim 5 wherein R^3 is fluorine, chlorine, bromine, C_{1-2} alkyl, C_{1-2} alkoxy, C_{1-2} alkylthio, C_{1-2} haloalkyl, C_{1-2} haloalkoxy, amino, mono(C_{1-2} alkyl)amino or di (C_{1-2} alkyl)amino.

7. (Previously presented) A composition according to claim 2, wherein R^4 is hydrogen or C_{1-2} alkyl.

8. (Previously presented) A composition according to claim 2, wherein X is -CO- or -CO-NR'- wherein R' represents hydrogen or a C_{1-2} alkyl group.

9. (Withdrawn) A composition according to claim 2, wherein R^5 is a 5- or 6- membered heterocyclyl, aryl or heteroaryl ring which is substituted by a C_{1-6} hydroxyalkyl group or a -(C_{1-4} alkyl)-X_1-(C_{1-4} alkyl)-X_2-(C_{1-4} alkyl) group, wherein X_1 and X_2 are as defined in claim 2.

10. (Withdrawn) A composition according to claim 9, wherein R^5 is a 5- or 6- membered heteroaryl group which is substituted by a $-CH_2-OH$ or -(C_{1-4} alkyl)-NR'-(C_{1-4} alkyl)-$S(O)_2$-(C_{1-4} alkyl) substituent, wherein R' is hydrogen or C_{1-2} alkyl.

11. (Previously presented) A composition according to claim 2, wherein A_1 is an aryl or heteroaryl group.

12. (Original) A composition according to claim 11, wherein A_1 is a phenyl group, a monocyclic 5- or 6- membered heteroaryl group or a 5- to 6- membered heteroaryl group fused to a monocyclic oxo-substituted 5- to 6- membered heterocyclyl group.

13. (Previously presented) A composition according to claim 2 wherein A_1 is unsubstituted or substituted by 1 or 2 substituents selected from halogen, cyano, nitro, C_{1-4} alkyl, C_{1-4} haloalkyl and C_{1-4} alkoxy substituents.

14. (Previously presented) A composition according to claim 2, wherein Y represents a direct bond, a C_{1-2} alkylene group, $-SO_2-$ or -O-.

15. (Previously presented) A composition according to claim 2 wherein A_2 is a phenyl, 5- to 6- membered heteroaryl, 5- to 6- membered heterocyclyl or C_{3-6} cycloalkyl group.

16. (Withdrawn) A composition according to claim 2, wherein when A_2 is a heterocyclyl group it is attached to the moiety Y via a N atom.

17. (Previously presented) A composition according to claim 2, wherein A_2 is unsubstituted or is substituted by 1 or 2 substituents which are selected from C_{1-4} alkyl and halogen substituents when A_2 is a heteroaryl or aryl group and which are selected from C_{1-4} alkyl, halogen and oxo substituents when A_2 is a carbocyclic or heterocyclyl group.

18. (Previously presented) A composition according to claim 2, wherein A_2 is a piperazinyl, pyridyl, morpholinyl, pyrrolidinyl, piperidinyl, pyrazinyl, cyclopropyl, phenyl or S,S-dioxo-thiomorpholino group, which is unsubstituted or substituted by a C_{1-2} alkyl group.

19. (Previously presented) A composition according to claim 2 wherein the benzodiazepine derivative of formula (V) is a benzodiazepine derivative of formula (Va):



(Va):

wherein:

X is -CO- or -CO-NH-; and

R^5 is a 5- to 6-membered heteroaryl group, for example a furanyl group, which is substituted by $-CH_2-OH$ or -(C_{1-4} alkyl)-$N(CH_3)$-(C_{1-4} alkyl)-SO_2-(C_{1-4} alkyl) or R5 represents $-A_1-Y-A_2$, wherein:

A_1 is a phenyl, pyridyl, furanyl, thiazolyl, oxazolyl, isoxazolyl, thienyl or 1H-imidazo[4,5-b]pyridin-2-(3H)-one moiety, which is unsubstituted or substituted by 1 or 2 substituents selected from halogen, cyano, C_{1-2} alkyl, C_{1-2} haloalkyl and C_{1-2} alkoxy substituents;

Y is a direct bond, a C_{1-2} alkylene group, $-SO_2-$ or -O-; and

A_2 is a piperazinyl, pyridyl, morpholinyl, pyrrolidinyl, piperidinyl, pyrazinyl, cyclopropyl, phenyl or S,S-dioxo-thiomorpholino group, which is unsubstituted or substituted by a C_{1-2} alkyl group.

20. (Original) A composition according to claim 1, wherein the benzodiazepine derivative of formula (V) is:

6-(4-Methyl-piperazin-1-yl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-nicotinamide;

3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-5'-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH- benzo[e][1,4]diazepin-3-yl)-amide;

(S)-2-(l,l-Dioxo-lλ6-thiomorpholin-4-yl)-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl-benzamide;

(S)-2-Chloro-4-morpholin-4-yl-N-(2-oxo-5-phenyl-2,3-dihydro- 1H-benzo[e][1 ,4] diazepin-3-yl)-benzamide;

(S)-2-(l,l-Dioxo-lλ6-thiomorpholin-4-yl)-4-fluoro-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl-benzamide;

(S)-5-Chloro-2-(1,1-dioxo-1λ6-thiomorpholin-4-yl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

(S)-2-(1,1-Dioxo-1λ6-thiomorpholin-4-yl)-5-fluoro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1 ,4]diazepin-3-yl)-benzamide;

(S)-5-(4-Methyl-piperazin-1-ylmethyl)-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro- lH-benzo[e][l,4]diazepin-3-yl)-amide;

(S)-5-Pyrrolidin-l-ylmethyl-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-5-Piperidin-1-ylmethyl-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-5-Dimethylaminomethyl-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-4-Fluoro-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-2-piperidin-1-yl-benzamide;

(S)-4-Fluoro-2-morpholino-4-yl-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4] diazepin-3-yl)-benzamide;

(S)-4-Cyano-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-2-pyrrolidin-l-yl-benzamide;

(S)-4-Cyano-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-piperidine-l-yl-benzamide;

(S)-N-(2-Oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-2-pyrrolidin-l-yl-4-trifluoromethyl-benzamide;

(S)-N-(2-Oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-2-piperidin-l-yl-4-trifluoromethyl-benzamide;

(S)-2-Morpholin-4-yl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-4-trifluoromethyl-benzamide;

(S)-N-(2-Oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-2-pyrrolidin- 1 -yl-5-trifluoromethyl-benzamide;

(S)-2-Morpholin-4-yl-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-5-trifluoromethyl-benzamide;

(S)-2-Morpholin-4-yl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-nicotinamide;

(S)-2-(l,l-Dioxo-lλ6-thiomorpholin-4-yl)-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-nicotinamide;

(S)-2-(l,l-Dioxo-lλ6-thiomorpholin-4-yl)-2-methyl-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-benzamide;

(S)-2-(l ,1-Dioxo- 1λ6-thiomorpholin-4-yl)-4-methyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

(S)-2-(l ,1 -Dioxo-1λ6-thiomorpholin-4-yl)-6-methyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H- benzo[e][1 ,4]diazepin-3-yl)-benzamide;

(S)-2-Chloro-6-(l ,1-dioxo- 1λ6-thiomorpholin-4-yl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H- benzo[e][1,4]diazepin-3-yl)-benzamide;

(S)-3-Cyclopropyl-2-oxo-2,3-dihydro-imidazo[4,5-b]pyridine-l-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-3-(4-Methyl-piperazine-1-sulfonyl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

(S)-4-(4-Methyl-piperazin-1-yl)-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4] diazepin-3-yl)-benzamide;

(S)-N-(2-Oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-3-(piperidine-l-sulfonyl)-benzamide;

(S)-3-(Morpholine-4-sulfonyl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-benzamide;

(S)-5-Morpholin-4-ylmethyl-furan-2-carboxylic acid(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-5-Hydroxymethyl-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-5-(l,l-Dioxo-lλ6-thiomorpholin-4-ylmethyl)-furan-2-carboxylic acid (2-oxo-5-phenyl- 2,3-dihydro-1H-benzo[e][1 ,4]diazepin-3-yl)-amide;

(S)-2-Chloro-4-(1, 1-dioxo-1λ6-thiomorpholin-4-yl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

(S)-2-Chloro-5-(1,1-dioxo-1λ6-thiomorpholin-4-yl)-N-(2-oxo-5-phenyl-2,3-dihydro- 1 H- benzo[e][1,4]diazepin-3-yl)-benzamide;

(S)-5-{[(2-Methanesulfonyl-ethyl)-methyl-amino]-methyl}-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl-amide;

(S)-2-Pyridin-3-yl-thiazole-4-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-2-Pyridin-4-yl-thiazole-4-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-4-Methyl-2-pyrazin-2-yl-thiazole-5-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-2-Morpholin-4-ylmethyl-furan-3-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e][1 ,4]diazepin-3-yl)-amide;

(S)-3-Morpholin-4-ylmethyl-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4] diazepin-3 -yl)-benzamide;

(S)-5-Morpholin-4-ylmethyl-isoxazole-3-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-l H- benzo[e][l,4]diazepin-3-yl)-amide;

(S)-3-Morpholin-4-ylmethyl-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1 ,4]diazepin-3-yl)-amide;

(S)-5-Pyridin-2-yl-thiophene-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-2-Methyl-4-(morpholin-4-sulfonyl)-furan-3-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-amide;

(S)-6-Morpholin-4-yl-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-nicotinamide;

(S)-3-Morpholin-4-ylmethyl-thiophene-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH- benzo[e][l,4]diazepin-3-yl)-amide;

(S)-5-Morpholin-4-ylmethyl-thiophene-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH- benzo[e][l,4]diazepin-3-yl)-amide;

2-Morpholin-4-yl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

(S)-5-Phenyl-oxazole-4 carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-amide;

1-(2-Oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-3-(4-phenoxy-phenyl)-urea

an N-oxide of any of the above compounds;

or a pharmaceutically acceptable salt thereof.

21. (Withdrawn) A composition according to claim 1, wherein the benzodiazepine derivative of formula (V) is (S)-5-(1,1-Dioxo-1λ6-thiomorpholin-4-ylmethyl)-furan-2-carboxylic acid (2- oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide or (S)-2-Chloro-4-morpholin-4-yl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide or a pharmaceutically acceptable salt thereof.

22. (Withdrawn) A composition according to claim 21, wherein the benzodiazepine derivative of formula (V) is (S)-5-(1, 1-Dioxo- 1λ6-thiomorpholin-4-ylmethyl)-furan-2-carboxylic acid (2- oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide or a pharmaceutically acceptable salt thereof.

23. (Previously presented) A composition according to claim 1 wherein component (a) is a compound of formula (I), or a pharmaceutically acceptable salt thereof, (I)



(I)

wherein:

X is H or C_{1-6} alkyl; said C_{1-6} alkyl being optionally substituted with halogen, $OCOR_4$ or $S(O)_n$- C_{1-6} alkyl;

Y is R_4, NR_4R_5, $NCOR_4$, =N-OR_4, -$CONHR_4$, $COOR_4$, -OR_4, aryl, heteroaryl, cyclyl or heterocyclyl, where R_4 and R_5 are H or C_{1-6} alkyl;

Z is CR_6R_7, where R_6 and R_7 are independently H, or straight, branched or cyclic C_{1-6} alkyl;

n is 1-6;

R_1 is $CONR_4R_5$, CO_2R_4 or C_{1-6} alkyl, said C_{1-6} alkyl can be optionally substituted with OR_4 or NR_8R_9;

R_8 and R_9 are each independently H, C_{1-6} alkyl, SO_2R_5, CO_2R_4 or COR_4;

R_2 is selected from the group consisting of NH_2, $CONR_6R_7$, heteroaryl, C_{2-6} alkenyl, CO_2R_4, N=CPh_2, C(=NH)NH_2 and C_{1-6} alkyl; said alkyl optionally substituted with a member selected from the group consisting of halogen, CN, $NR_{10}R_{11}$, OSO_2R_4 and OR_4; R_9 and R_{10} are

each independently selected from the group consisting of H, C_{1-6} alkyl, C_{3-6}cycloalkyl, CO_2R_4, COR_4 and SO_2R_4;

R_3 is selected from the group consisting of (1) CO_2R_9; (2) C_{1-6} alkyl optionally substituted with CN, OR_4 or NR_6R_7; and (3) C_{2-6} alkenyl substituted with CN;

Q is a member selected from the group consisting of

A is C or N, optionally substituted with H, halogen, straight, branched or cyclic C_{1-6} alkyl, C_{2-6} alkenyl, CO_2R_4, aryl or C_{3-6} cycloalkyl wherein when A is carbon, it may also be optionally substituted by O or S via a double bond;

B is C or N; wherein when B is C it may be optionally substituted by H, C_{1-6} alkyl, NO_2, CN, halogen, COR_4, $COOR_4$, $CONHR_4C(=NH)NH_2$ or $C(=NOH)NH_2$.

24. (Original) A composition according to claim 23 wherein component (a) is a compound of general formula (I), as defined above, or a pharmaceutically acceptable salt thereof, wherein at least two of R_1, R_2 and R_3 are hydrogen, and the other is hydrogen or -C(NH)-NH_2 and/or -X-Y is H, or X is a C_{1-6} alkylene group which is unsubstituted or substituted by a hydroxy group and Y is H, OH, CN, -NR'R", -COR', -SO_2R' or phenyl, wherein R' and R" are the same or different and represent a C_{1-6} alkyl group and/or Z is -CH_2- and/or Q is a moiety



wherein B is -CH- or -N-, A_1 is -C(O)- or -NH- and A_2 is -CH_2-, -CHR'- or –NR"-, wherein R' is a halogen atom and R" represents a hydrogen atom or a C_{1-4} alkyl, C_{2-4} alkenyl, C_{3-6} cycloalkyl, -SO_2-(C_{1-6} alkyl), -SO_2-N(C_{1-6} alkyl)$_2$ or -$(CO\text{-}NH)_a$-(C_{1-4} alkyl)-phenyl group, wherein a is 0 or 1, which group is unsubstituted or is substituted with a hydroxy or cyano substituent.

25. (Withdrawn) A composition according to claim 1 wherein component (a) is a compound of formula (II), or a pharmaceutically acceptable salt thereof,



(II)

wherein:

L_1 is $-CH_2-$ or $-CHR_2-CO-$;

each X is the same or different and CH or N;

each R_1 is the same or different and is C_{1-6} alkyl, halogen, hydroxy, phenyl or $(CH_2)_m{=}NH_2$;

n is 1 or 2;

R_2 is C_{1-6} alkoxy or C_{1-6} alkoxy-phenyl;

R_3 is C_{1-6}alkyl;

L_2 is $-CH_2-$ or -NH-;

Y is C_{1-6} alkyl or C_{1-6} alkenyl;

Z is H, $N(R_4)_2$, $-C(=O)-R_5$, $-C(=CH_2)-R_5$, $-CH(OH)-R_5$, $-CH(CH_3)-R_5$, $-CH(OCH_3)-R_5$;

each R_4 is the same or different and is H, C_{1-6} alkyl;

R_5 is C_{1-6} alkyl-carbonyl, amino, hydroxyl, aryl, heteroaryl, carbocyclyl, heterocyclyl;

and m = 1-6.

26. (Previously presented) A composition according to claim 1, wherein component (a) is:

1-Cyclopropyl-3-[1-(4-hydroxy-butyl)-1H-benzoimidazol-2-ylmethyl]-1,3-dihydro-imidazo[4,5-c]pyridin-2-one

{2-[2-(l,2-Dihydro-benzotriazol-l-ylmethyl)-benzoimidazol-l-yl]ethyl}-diethyl-amine

{2-[2-(3-Iodo-2,3-dihydro-indazol-l-ylmethyl)-benzimidazol-l-yl]-ethyl}-dimethyl-amine

1-Isopropenyl-3-[1-(3 -methyl-butyl)-1H-benzoimidazol-2-ylmethyl]-1,3-dihydro-benzoimidazol-2-one

1-(4-Hydroxy-benzyl)-3-[1-(3-methyl-butyl)-1H-benzoimidazol-2-ylmethyl]-1,3-dihydro-benzoimidazol-2-one

1-Isopropenyl-3-[1-(3-oxo-butyl)-1H-benzoimidazol-2-ylmethyl]-1,3-dihydro-benzoimidazol-2-one

1-Ethyl-3-[1-(2-hydroxy-2-phenyl-ethyl)-1H-benzoimidazol-2-ylmethyl]-1,3-dihydro-benzoimidazol-2-one

1-Ethyl-3-[1-(4-hydroxy-butyl)-1H-benzoimidazol-2-ylmethyl]-1,3-dihydro-benzoimidazol-2-one

7-[2-(3-Isopropenyl-2-oxo-2,3-dihydrobenzoimidazol-1-ylmethyl)-benzoimidazol-1-yl]-heptanenitril

5-{3-[1-(3-Methanesulfonyl-propyl)-lH-benzoimidazol-2-ylmethyl]-2-oxo-2,3-dihydro-benzoimidazol-1-yl}-pentanenitrile

3-[1-(3-Methyl-butyl)-1H-benzoimidazol-2-ylmethyl]-2-oxo-2,3-dihydro-benzoimidazol-1-carboxylic acid benzylamide

1-Methanesulfonyl-3-[1-(3-methyl-butyl)-lH-benzoimidazol-2-ylmethyl]-1,3-dihydro-benzoimidazol-2-one

3-[1-(3-Methyl-butyl)-1H-benzoimidazol-2-ylmethyl]-2-oxo-2,3-dihydro-benzoimidazol-1 -sulfonic acid dimethylamide

1-Isopropenyl-3-(1-propyl-lH-benzoimidazol-2-ylmethyl)-1,3-dihydro-imidazo[4,5-c]pyridine-2-one

Bis(5-amidino-2-benzimidazolyl)-methane

2-{2-[1-[1-(2-Amino-ethyl)-piperidin-4-ylamino]-4-methyl-benzoimidazol-1-ylmethyl}-6-methyl-pyridin-3-ol

or a pharmaceutically acceptable salt thereof.

27. (Previously presented) A composition according to claim 1, wherein component (a) is 1-cyclopropyl-3-[1-(4-hydroxy-butyl)-1H-benzoimidazol-2-ylmethyl]-1,3-dihydro-imidazo[4,5-c]pyridin-2-one, {2-[2-(1 ,2-dihydro-benzotriazol-1-ylmethyl)-benzoimidazol-1-yl]ethyl}-diethyl-amine, {2-[2-(3 -iodo-2,3-dihydro-indazol-1-ylmethyl)-benzimidazol-1-yl]-ethyl}-dimethyl-amine or a pharmaceutically acceptable salt thereof.

28. (Previously presented) A composition according to claim 1, wherein component (a) is 1-cyclopropyl-3-[1-(4-hydroxy-butyl)-lH-benzoimidazol-2-ylmethyl]-l,3-dihydro-imidazo[4,5-

c]pyridin-2-one or 1-Isopropenyl-3-(1-propyl-1H-benzoimidazol-2-ylmethyl)-1,3-dihydro-imidazo[4,5-c]pyridine-2-one or a pharmaceutically acceptable salt thereof.

29. (Previously presented) A composition according to claim 1 wherein component (a) is present in an amount of from 0.025 wt% to 10 wt%.

30. (Previously presented) A composition according to claim 1 wherein component (b) is present in an amount of 0.025 wt% to 10 wt%.

31. (Previously presented) A composition according to claim 1, for use in the treatment of the human or animal body.

32. (Previously presented) Use of: (a) an RSV fusion protein inhibitor as defined in claim 1; and (b) a benzodiazepine derivative defined in claim 1, in the manufacture of a medicament for use in treating or preventing an RSV infection.

33. (Previously presented) Use according to claim 32, wherein component (a) is present in an amount of from 0.025 wt% to 10 wt% and component (b) is present in an amount of 0.025 wt% to 10 wt%.

34. (Previously presented) A product comprising: (a) an RSV fusion protein inhibitor as defined in claim 1; and (b) a benzodiazepine derivative as defined in claim 1; for separate, simultaneous or sequential use in the treatment of the human or animal body.

35. (Original) A product according to claim 34 for separate, simultaneous or sequential use in treating or preventing an RSV infection.

36. (Previously presented) A method of treating or preventing an RSV infection in a patient, which method comprises the administration to said patient of: (a) an RSV fusion protein inhibitor as defined in claim 1; and (b) a benzodiazepine derivative as defined in claim 1.

37. (Previously presented) Use of an RSV fusion protein inhibitor as defined in claim 1, in the manufacture of a medicament for use in treating or preventing an RSV infection, by co-administration with a benzodiazepine derivative as defined in claim 1.

38. (Previously presented) Use of a benzodiazepine derivative as defined in claim 1, in the manufacture of a medicament for use in treating or preventing an RSV infection, by co-administration with an RSV fusion protein inhibitor as defined in claim 1.